Recent research into Amyotrophic Lateral Sclerosis (ALS) highlights the complex interplay of factors contributing to the disease's progression. A study by Gorgich et al. (2025) suggests that brain metabolite profiles are linked to selective neuronal vulnerability, which could provide insights into underlying mechanisms. This implies that certain chemical changes in the brain might be associated with why some neurons are more susceptible to damage than others.
Understanding these metabolite profiles could help researchers develop targeted treatments for ALS. The disease involves the degeneration of motor neurons, leading to muscle weakness and loss of control. Other studies have shown that genetic factors, such as mutations in genes like SOD1 and C9ORF72, play a significant role in ALS pathology. Additionally, alterations in lipid metabolism have been identified as potential contributors to the selective vulnerability of certain motor neurons in ALS[5]. These findings collectively contribute to a deeper understanding of ALS and may pave the way for more effective therapeutic strategies.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar 